Rigel Pharmaceuticals | RIGL - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
Agenus USD -221.22M 49.89M 2026-03
Amgen USD 9.19B 532M 2026-03
Anika Therapeutics USD 133.9M 9.56M 2026-03
Arrowhead Research USD 613.98M 45.56M 2026-03
AstraZeneca USD 47.33B 1.33B 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Celldex Therapeutics USD 456.23M 70.94M 2026-03
Daiichi Sankyo JPY 1.71T 57.86B 2025-12
Eli Lilly USD 31.2B 4.66B 2026-03
Halozyme Therapeutics USD 219.64M 170.82M 2026-03
Heron Therapeutics USD 9.14M 4.15M 2026-03
Intrexon USD 43.17M 75.33M 2024-06
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
Karyopharm Therapeutics USD -292.93M 23.67M 2025-12
Ligand Pharmaceuticals USD 997.32M 19.89M 2026-03
MacroGenics USD 21.2M 34.39M 2026-03
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Veracyte USD 1.34B 34.83M 2026-03